TIP_link_300x300.jpg
Cardiac Monitoring Devices Market Size Worth $43.33Bn, Globally, by 2028 at 6.4% CAGR - Exclusive Report by The Insight Partners
01 avr. 2022 05h37 HE | The Insight Partners
New York, April 01, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Cardiac Monitoring Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type...
Clinical Data Evaluating Gencaro for the Treatment of Atrial Fibrillation in Heart Failure Patients Featured in Three Presentations at the 2020 Heart Rhythm Scientific Sessions
07 mai 2020 08h30 HE | ARCA biopharma, Inc.
New data provide additional evidence of efficacy for Gencaro compared to active control in a pharmacogenetically-defined HF population at risk for AF recurrence °  26% reduction in total time spent...
ARCA Biopharma Announces First Quarter 2020 Financial Results And Provides Corporate Update
06 mai 2020 16h30 HE | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for PRECISION-AF, a single pivotal Phase 3 clinical trial of genetically targeted GencaroPRECISION-AF trial to evaluate Gencaro as a potential treatment...
ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update
18 févr. 2020 16h30 HE | ARCA biopharma, Inc.
U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth...
ARCA Logo - JPEG.jpg
ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium
12 sept. 2019 08h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting
11 sept. 2019 08h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
RL Logo.jpg
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of HF, WCG, and STI of Class Action Lawsuits Filed
06 juin 2019 12h13 HE | Rigrodsky & Long, P.A.
WILMINGTON, Del., June 06, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. reminds investors that it has commenced class action lawsuits against the following companies: HFF, Inc. (NYSE: HF) ...
RL Logo.jpg
Rigrodsky & Long, P.A. Files Class Action Suit Against HFF, Inc.
10 mai 2019 18h05 HE | Rigrodsky & Long, P.A.
WILMINGTON, Del., May 10, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A.: Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court...
RL Logo.jpg
MSL, HOFD, and HF SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
01 mai 2019 13h44 HE | Rigrodsky & Long, P.A.
WILMINGTON, Del., May 01, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: MidSouth Bancorp, Inc. (NYSE: MSL) regarding possible violations of law related to...
GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
01 mai 2019 08h30 HE | ARCA biopharma, Inc.
WESTMINSTER, Colo., May 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...